Get the Stockscreener App
2.44
3.94%
-0.10
Pre-market:
2.44
Allurion Technologies Inc stock is traded at $2.44, with a volume of 54,240.
It is down -3.94% in the last 24 hours and down -53.35% over the past month.
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
See More
Previous Close:
$2.54
Open:
$2.48
24h Volume:
54,240
Relative Volume:
0.04
Market Cap:
$14.55M
Revenue:
$34.75M
Net Income/Loss:
$-24.76M
P/E Ratio:
-0.2033
EPS:
-12
Net Cash Flow:
$-50.91M
1W Performance:
-4.69%
1M Performance:
-53.35%
6M Performance:
-84.13%
1Y Performance:
-96.53%
1-Day Range:
$2.34
$2.50
1-Week Range:
$2.15
$2.60
52-Week Range:
$2.15
$98.75
Allurion Technologies Inc Stock (ALUR) Company Profile
Name
Allurion Technologies Inc
Sector
Industry
Phone
508-647-4000
Address
11 HURON DR STE 200, NATICK
Compare ALUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
2.44 | 14.55M | 34.75M | -24.76M | -50.91M | -12.00 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-02-24 | Initiated | TD Cowen | Buy |
| Sep-06-24 | Initiated | ROTH MKM | Buy |
| Feb-09-24 | Initiated | Jefferies | Buy |
Allurion Technologies Inc Stock (ALUR) Latest News
Allurion Technologies (ALUR) Projected to Post Quarterly Earnings on Thursday - Defense World
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025 - The Bakersfield Californian
Q1 EPS Forecast for Allurion Technologies Cut by Analyst - Defense World
Allurion Technologies price target lowered to $16 on split-adjusted basis - TipRanks
Allurion Balloon Reintroduced in France - MPO-mag
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - BioSpace
Allurion Technologies announces issuance of new patents on weight loss device - TipRanks
Allurion Announces Notification Of Issuance Of New U.S. Patents On Next-Generation Weight Loss Device For The Treatment Of Obesity - Marketscreener.com
Allurion's New Patents Could Transform Obesity Treatment: What's Behind Their Swallowable Balloon Technology? - StockTitan
Allurion to Participate in Upcoming Investor Conferences - 01Net
Allurion to Participate in Upcoming Investor Conferences -February 25, 2025 at 04:06 pm EST - Marketscreener.com
Can Allurion's Anti-Obesity Strategy Impress Investors at Major Healthcare Conferences? - StockTitan
ALURALLURION TECHNOLOGIES INC Latest Stock News & Market Updates - StockTitan
Allurion to raise $6.1 million in direct offering and private placement - MSN
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline - BioSpace
Can Allurion's Balloon-GLP-1 Combo Reshape Weight Loss Treatment? $6.1M Bet Says Yes - StockTitan
Allurion announces $6.1 million stock and warrant sale By Investing.com - Investing.com South Africa
Allurion announces $6.1 million stock and warrant sale - Investing.com
Allurion Tech dips on $6.1 million stock offering - TradingView
S&P 500 Edges Higher; Analog Devices Earnings Top Views - Benzinga
Stock market news: Allurion Technologies -31.00%, Bumble -28.09% among biggest losers during midday trading - Business Upturn
Allurion Technologies Expects to Raise $6.1 Million From Stock Offering; Shares Plunge - Marketscreener.com
Dow Dips 150 Points; US Housing Starts Fall In January - Benzinga
Allurion to sell 900,000 shares at $5.23 in registered direct offering - TipRanks
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline - Business Wire
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity - BioSpace
Allurion stock soars 70% on weight-loss therapy update - MSN
Allurion to study balloon and GLP-1 therapy combo - Investing.com
Allurion to study balloon and GLP-1 therapy combo By Investing.com - Investing.com South Africa
Allurion Technologies to initiate Allurion Balloon with GLP-1 agonists study - TipRanks
Allurion cleared to resume sale of swallowable gastric balloon in France - BioWorld Online
Allurion Technologies relaunches in France - TipRanks
ANSM Clears Allurion To Resume Sales Of Allurion Balloon -February 13, 2025 at 08:40 am EST - Marketscreener.com
Allurion Relaunches in France - Business Wire
Allurion Technologies Touts Positive Study Results for its Weight Loss Balloon - MPO-mag
How Much Upside is Left in Allurion Technologies, Inc. (ALUR)? Wall Street Analysts Think 374.67% - MSN
Allurion announces study on obesity treatment enhancement - MSN
12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session - Benzinga
This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here. - MSN
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
11 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session - Benzinga
Allurion Technologies Soars 200% Amid Stock Offering and New Clinical Study Plans for Weight Loss Product - HPBL
Allurion Technologies Shares Surge as Company Eyes Obesity Drug Market with Gastric Balloon-GLP-1 Combo - HPBL
Allurion Technologies Inc Stock (ALUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):